Anti-infection and anti-tumor mucosal immune preparation

Abstract

An immune preparation includes an immune substance formed by polyinosinic-polycytidylic acid, a non-antibiotic amino compound, polyethyleneimine, and at least one metal ion. The immune preparation does not include any antibiotics to prevent potential side effects. The amino compound may be chitosan oligosaccharide. The immune preparation is suitable for mucosal administration. The mucosal immune preparation facilitates mucosal immunity of human body allowing for the activation and proliferation of various immune cells.

What is claimed is: 
     
         1 . An immune preparation, comprising an immune substance formed by polyinosinic-polycytidylic acid, a non-antibiotic amino compound, polyethyleneimine (PEI), and at least one metal ion, wherein the immune preparation is suitable for mucosal administration, and wherein the immune preparation does not contain an antibiotic. 
     
     
         2 . The immune preparation of  claim 1 , wherein the non-antibiotic amino compound is chitosan oligosaccharide, and the chitosan oligosaccharide has a molecular weight of less than 3200 Da. 
     
     
         3 . The immune preparation of  claim 2 , wherein the immune preparation is a spray or an aerosol. 
     
     
         4 . The immune preparation of  claim 2 , wherein the immune preparation comprises a propellant. 
     
     
         5 . The immune preparation of  claim 2 , wherein the metal ion is Ca′. 
     
     
         6 . The immune preparation of  claim 2 , wherein the immune substance has a particle size of less than 1000 nm. 
     
     
         7 . The immune preparation of  claim 2 , wherein the immune preparation further comprises at least one of antigens, chemical drugs and biological immune drugs. 
     
     
         8 . A method for anti-infection of a subject having at least one of a viral infection, bacterial infection and parasitic infection, the method comprising:
 administering, via a mucosal administration route, the immune preparation of  claim 2  to the subject in need thereof.   
     
     
         9 . The method of  claim 8 , wherein the mucosal administration route is transnasal. 
     
     
         10 . A method of treating a subject having a metastatic carcinoma, the method comprising:
 administering, via a mucosal administration route, the immune preparation of  claim 2  to the subject in need thereof.   
     
     
         11 . The method of  claim 10 , wherein the mucosal administration route is transnasal. 
     
     
         12 . An immune preparation, comprising an immune substance formed by polyinosinic-polycytidylic acid, polyethyleneimine (PEI)-grafted chitosan oligosaccharide, and at least one metal ion, wherein the immune preparation is suitable for mucosal administration, and wherein the immune preparation does not contain an antibiotic, and chitosan oligosaccharide in the PEI-grafted chitosan oligosaccharide has a molecular weight of less than 3200 Da. 
     
     
         13 . The immune preparation of  claim 12 , wherein the immune preparation is a spray or an aerosol. 
     
     
         14 . The immune preparation of  claim 12 , wherein the immune preparation comprises a propellant. 
     
     
         15 . The immune preparation of  claim 12 , wherein the metal ion is Ca′. 
     
     
         16 . The immune preparation of  claim 12 , wherein the immune preparation further comprises at least one of antigens, chemical drugs and biological immune drugs. 
     
     
         17 . A method for anti-infection of a subject having at least one of a viral infection, bacterial infection and parasitic infection, the method comprising:
 administering, via a mucosal administration route, the immune preparation of  claim 12  to the subject in need thereof.   
     
     
         18 . The method of  claim 17 , wherein the mucosal administration route is transnasal. 
     
     
         19 . A method of treating a subject having a metastatic carcinoma, the method comprising:
 administering, via a mucosal administration route, the immune preparation of  claim 12  to the subject in need thereof.   
     
     
         20 . The method of  claim 19 , wherein the mucosal administration route is transnasal.